An update on PARP inhibitors - Moving to the adjuvant setting

Nature Reviews Clinical Oncology

Volumn 12, Issue 1, 2015, Pages 27-41

  Sonnenblick, Amir ^a   De Azambuja, Evandro ^a   Azim, Hatem A ^a   Piccart, Martine ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CEP 9722; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; RUCAPARIB; TALAZOPARIB; VELIPARIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; CARBOPLATIN; DEOXYCYTIDINE; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHARMACEUTICAL VEHICLES AND ADDITIVES; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ADVANCED CANCER; ANEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; DNA REPAIR; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HETEROZYGOTE; HUMAN; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; REVIEW; SOLID TUMOR; STOMACH CANCER; TUMOR SUPPRESSOR GENE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DOUBLE STRANDED DNA BREAK; FEMALE; GENETICS; SINGLE STRANDED DNA BREAK;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; BENZAMIDES; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARBOPLATIN; DEOXYCYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; FEMALE; HUMANS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84925270121     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.163     Document Type: Review

References (101)

1. Amé, J.-C., Spenlehauer, C. &de Murcia, G. The PARP superfamily. Bioessays 26, 882-893 (2004).
2. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
3. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
4. Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30, 1879-1887 (2012).
5. Anders, C. K. et al. Poly(ADP-ribose) polymerase inhibition: 'targeted' therapy for triple-negative breast cancer. Clin. Cancer Res. 16, 4702-4710 (2010).
6. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
7. Virág, L. &Szabó, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375-429 (2002).
8. Malanga, M. &Althaus, F. R. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell Biol. 83, 354-364 (2005).
9. Shall, S. &de Murcia, G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460, 1-15 (2000).
10. Tucker, C. L. &Fields, S. Lethal combinations. Nat. Genet. 35, 204-205 (2003).
11. Turner, N., Tutt, A. &Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
12. Lee, J.-M., Ledermann, J. A. &Kohn, E. C. PARP Inhibitors for BRCA1/2 mutation-Associated and BRCA-like malignancies. Ann. Oncol. 25, 32-40 (2014).
13. Alli, E., Sharma, V. B., Sunderesakumar, P. &Ford, J. M. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 69, 3589-3596 (2009).
14. Hastak, K., Alli, E. &Ford, J. M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70, 7970-7980 (2010).
15. O'Shaughnessy, J. et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [abstract]. J. Clin. Oncol. 29 (Suppl.), a1007 (2011).
16. O'Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
17. Guarini, A. et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica 97, 47-55 (2012).
18. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
19. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
20. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
21. Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5, 387-393 (2011).
22. Schreiber, V., Dantzer, F., Amé, J.-C. &de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7, 517-528 (2006).
23. Ekblad, T., Camaioni, E., Schüler, H. &Macchiarulo, A. PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 280, 3563-3575 (2013).
24. d'Adda di Fagagna, F. et al. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat. Genet. 23, 76-80 (1999).
25. Shi, L. et al. Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J. Biol. Chem. 283, 36474-36485 (2008).
26. Rulten, S. L. et al. PARP-3 and APLF function together to accelerate nonhomologous end-joining. Mol. Cell 41, 33-45 (2011).
27. Boehler, C. et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl Acad. Sci. USA 108, 2783-2788 (2011).
28. Riffell, J. L., Lord, C. J. &Ashworth, A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 11, 923-936 (2012).
29. Patel, A. G., Sarkaria, J. N. &Kaufmann, S. H. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl Acad. Sci. USA 108, 3406-3411 (2011).
30. Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588-5599 (2012).
31. Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8-R17 (2004).
32. Rennert, G. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 357, 115-123 (2007).
33. Mavaddat, N. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol. Biomarkers Prev. 21, 134-147 (2011).
34. Cameron, D. et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 14, 933-942 (2013).
35. Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275-1281 (2008).
36. Von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796-1804 (2012).
37. Neri, P. et al. Phase I study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma. Presented at the 54th ASH Annual Meeting and Exposition (2012).
38. Samol, J. et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest. New Drugs 30, 1493-1500 (2012).
39. Khan, O. A. et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer 104, 750-755 (2011).
40. Penson, R. T. et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), a5004 (2011).
41. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382-1392 (2012).
42. Campone, M. et al. Phase I dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CEP-9722 (a PARP1-2 inhibitor) as single-Agent and in combination with temozolomide in patients with advanced solid tumors (NCT00920595) [abstract]. J. Clin. Oncol. 30 (Suppl.), a3052 (2012).
43. Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. &Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655-1662 (2012).
44. Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861 (2011).
45. Schelman, W. R. et al. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers [abstract]. J. Clin. Oncol. 28 (Suppl.), a3001 (2010).
46. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
47. Drew, Y. et al. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), a3104 (2011).
48. De Bono, J. S. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors [abstract] J. Clin. Oncol. 31 (Suppl.), a2580 (2013).
49. Sandhu, S. K. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 14, 882-892 (2013).
50. Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244 (2010).
51. Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251 (2010).
52. Kaufman, B. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: an open-label phase II study [abstract]. J. Clin. Oncol. 31 (Suppl.), a11024 (2013).
53. Ledermann, J. et al. Randomized trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis by BRCA mutation status. Lancet Oncol. 15, 852-861 (2014).
54. Kaye, S. B. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372-379 (2012).
55. Konstantinopoulos, P. A. &Cannistra, S. A. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial. J. Clin. Oncol. 30, 347-350 (2012).
56. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. &Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273, 5858-5868 (1998).
57. Lowndes, N. F. &Toh, G. W.-L. DNA repair: the importance of phosphorylating histone H2AX. Curr. Biol. 15, R99-R102 (2005).
58. Bonner, W. M. et al. ?H2AX and cancer. Nat. Rev. Cancer 8, 957-967 (2008).
59. Bouwman, P. &Jonkers, J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 20, 540-547 (2014).
60. Lord, C. J. &Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363-369 (2008).
61. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
62. Oddoux, C. et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet. 14, 188-190 (1996).
63. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
64. Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008).
65. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
66. Barber, L. J. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422-429 (2013).
67. Jaspers, J. E. et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3, 68-81 (2013).
68. Fojo, T. &Bates, S. Mechanisms of resistance to PARP inhibitors-three and counting. Cancer Discov. 3, 20-23 (2013).
69. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008).
70. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02032823?term=Olympia&rank=1 (2014).
71. Huggins-Puhalla, S. L. et al. A phase I study of chronically dosed, single-Agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt) [abstract]. J. Clin. Oncol. 30 (Suppl.), a3054 (2012).
72. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01506609?term=NCT01506609&rank=1 (2014).
73. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01074970?term=NCT01074970&rank=1 (2013).
74. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT00664781?term=NCT00664781&rank=1 (2013).
75. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01945775?term=NCT01945775&rank=1 (2014).
76. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02034916?term=NCT02034916&rank=1 (2014).
77. Miknyoczki, S. et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 6, 2290-2302 (2007).
78. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01847274?term=NCT01847274&rank=1 (2014).
79. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01905592?term=NCT01905592&rank=1 (2014).
80. Yamamoto, N. et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 103, 504-509 (2012).
81. Dean, E. et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br. J. Cancer 106, 468-474 (2012).
82. Oza, A. M. et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study [abstract]. J. Clin. Oncol. 30 (Suppl.), a5001 (2012).
83. Bang, Y.-J. et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study [abstract]. J. Clin. Oncol. 31 (Suppl.), a4013 (2013).
84. Rajan, A. et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin. Cancer Res. 18, 2344-2351 (2012).
85. Kummar, S. et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27, 2705-2711 (2009).
86. Kummar, S. et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626-5634 (2011).
87. Bell-McGuinn, K. M. et al. Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2584 (2013).
88. Pishvaian, M. J. et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer [abstract]. J. Clin. Oncol. 29 (Suppl.), a3502 (2011).
89. Hussain, M. Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a224 (2012).
90. He, A. R. et al. Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 32 (Suppl.), a240 (2014).
91. Kummar, S. et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin. Cancer Res. 18, 1726-1734 (2012).
92. Rhoda Molife, L. et al. A phase 1 study of oral rucaparib in combination with carboplatin [abstract]. J. Clin. Oncol. 31 (Suppl.), a2586 (2013).
93. Kristeleit, R. S. et al. A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2585 (2013).
94. Plummer, R. et al. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother. Pharmacol. 71, 1191-1199 (2013).
95. Liu, J. F. et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-Angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur. J. Cancer 49, 2972-2978 (2013).
96. Dent, R. A. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res. 15, R88 (2013).
97. Bundred, N. et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest. New Drugs 31, 949-958 (2013).
98. Isakoff, S. J. et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract]. J. Clin. Oncol. 28 (Suppl.), a1019 (2010).
99. Lee, J.-M. et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-Associated breast or ovarian cancer with biomarker analyses. J. Natl Cancer Inst. 106, dju089 (2014).
100. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01874353?term=NCT01874353&rank=1 (2014).
101. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01844986?term=NCT01844986&rank=1 (2014).